<DOC>
	<DOC>NCT01224028</DOC>
	<brief_summary>This study is to evaluate efficacy and safety of tacrolimus in the patients with non-nephrotic albuminuric, normotensive IgA nephropathy after 16 week treatment with tacrolimus (Prograf) or placebo.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis, IGA</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Patients with IgA nephropathy confirmed by renal biopsy Serum creatinine measurement ≤1.5mg/ml or MDRD estimated GFR ≥ 45ml/min/1.73m2 (MDRD: Modification of Diet in Renal Disorder) UACR level between 0.3 and 3.0 Blood pressure measurements &lt; 130/80mmHg Use of immunosuppressants for more than two weeks within last one month Concomitant use of ACE inhibitor, ARB, steroids or immunosuppressant, NDHPCCB, diuretics, omega3 fatty acids and its analogue &amp; additional dietary to treat igA nephropathy (ACE: Angiotensin Converting Enzyme, ARB: Angiotensin Receptor Blocker, NDHPCCB: Nondihydropyridinetype Calcium Channel Blocker Pregnant or breastfeeding patients. Patients who plan to bear children or breastfeed during the study and within 6 month after completion of study Hypersensitivity to the investigational drug or macrolide agents Use of potassiumsparing diuretics Persistence of liver function abnormality more than 1 month or presence of acute active hepatitis Other investigational drug within last 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
	<keyword>Calcinurin inhibitor</keyword>
	<keyword>Albuminurea</keyword>
	<keyword>Proteinurea</keyword>
	<keyword>FK506</keyword>
</DOC>